<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2249">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131880</url>
  </required_header>
  <id_info>
    <org_study_id>CIPI/21/032</org_study_id>
    <nct_id>NCT05131880</nct_id>
  </id_info>
  <brief_title>Gait Re-education Program in Subjects With Parkinson´s Disease</brief_title>
  <official_title>Effectiveness of a Gait Re-education Program on a Sequential Square Treadmill (Tapiz Fisior) in Subjects With Parkison´s Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Europea de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Europea de Madrid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized controlled study that will include participants diagnosed with Parkinson's disease&#xD;
      in mild or moderate stage with altered gait pattern who will be randomized following a simple&#xD;
      randomization procedure in which one group will perform an intervention based on a gait&#xD;
      re-education program called &quot;TAPIZ FISIOR&quot;- motor control and learning added to a&#xD;
      conventional physiotherapy program; and the other group will perform only a conventional&#xD;
      physiotherapy program. The evaluators will be unaware of the patient's treatment status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants interested in participating in the present study will be part of the&#xD;
      research project. Once recruited, they will be randomly assigned to two intervention groups:&#xD;
      A and B. Group A (control group) will perform a conventional physiotherapy treatment 2/3&#xD;
      sessions per week of 30 minutes duration; on the other hand, group B (intervention group)&#xD;
      will perform the treatment of group A and a therapeutic supplement of 2-3 sessions per week&#xD;
      of about 30 minutes. During the research period, several measurements of the variables&#xD;
      studied will be taken: one before the intervention, one immediately after the end of the&#xD;
      intervention, and another measurement 12 weeks after the end of the intervention.&#xD;
&#xD;
      The treatment will be carried out and supervised at all times by qualified physiotherapists,&#xD;
      who will explain to you what the treatment consists of, the days you should attend, and the&#xD;
      schedules. No adverse effects are expected from this therapy that could pose a risk for&#xD;
      health.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Balance and Walk</measure>
    <time_frame>15 min</time_frame>
    <description>Short Physical Performance Battery test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fall Risk on elderly</measure>
    <time_frame>15 min</time_frame>
    <description>Timed Up and Go test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fall Risk</measure>
    <time_frame>10 min</time_frame>
    <description>Fall Skip</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functionality and independence</measure>
    <time_frame>20 min</time_frame>
    <description>Barthel Index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>General Satisfaction</measure>
    <time_frame>10 min</time_frame>
    <description>General satisfaction test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental group will participate in a physiotherapy program with the addition of the Fisior Tapestry Method physiotherapy program, three sessions per week, for 12 weeks.&#xD;
An initial assessment will be made at the beginning of the study, another one at the end of the intervention, and another one at follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will participate in a physiotherapy program three sessions per week for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GAIT RE-EDUCATION PROGRAM ON A SEQUENTIAL MAT IN SUBJECTS WITH PARKINSON'S DISEASE</intervention_name>
    <description>Randomized controlled study that will include participants diagnosed with Parkinson's disease in mild or moderate stage with altered gait pattern who will be randomized following a simple randomization procedure in which one group will perform an intervention based on a gait re-education program called &quot;TAPIZ FISIOR&quot;- motor control and learning added to a conventional physiotherapy program; and the other group will perform only a conventional physiotherapy program. The evaluators will be unaware of the patient's treatment condition.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Older than 50 years.&#xD;
&#xD;
          -  Diagnosed Parkinson Disease.&#xD;
&#xD;
          -  Not to be institutionalized.&#xD;
&#xD;
          -  Barthel index scores of ≥ 60.&#xD;
&#xD;
          -  Ability to communicate and to get up and walk at least 10 m (33 ft)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical criteria for contraindication of treatment.&#xD;
&#xD;
          -  Severe behavioral problems that hinder participation in the training program.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alberto Bermejo Franco, PhD</last_name>
    <phone>+34656932144</phone>
    <email>alberto.bermejo@universidadeuropea.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>José Alegre Tamariz, MsC</last_name>
    <phone>+34653758181</phone>
    <email>yualegre@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alberto Bermejo Franco</name>
      <address>
        <city>Villaviciosa de Odón</city>
        <state>Madrid</state>
        <zip>28670</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Bermejo Franco, PhD</last_name>
      <phone>+34656932144</phone>
      <email>alberto.bermejo@universidadeuropea.es</email>
    </contact>
    <contact_backup>
      <last_name>José Alegre Tamariz, MsC</last_name>
      <phone>+34653758181</phone>
      <email>yualegre@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 20, 2021</last_update_submitted>
  <last_update_submitted_qc>November 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Europea de Madrid</investigator_affiliation>
    <investigator_full_name>Alberto Bermejo Franco</investigator_full_name>
    <investigator_title>Alberto Bermejo Franco</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

